Saturday, 20 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Grvt Raises M to Pioneer Privacy-First Onchain Finance and Unlock Trillion-Dollar Markets
    Grvt Raises $19M to Pioneer Privacy-First Onchain Finance and Unlock Trillion-Dollar Markets
    19/09/2025
    Global Roadshows Drive Momentum for the 138th Canton Fair
    Global Roadshows Drive Momentum for the 138th Canton Fair
    19/09/2025
    Bigg Boss 19: Nominations Drama Unfolds – Who’s Safe and Who’s at Risk?
    Bigg Boss 19: Nominations Drama Unfolds – Who’s Safe and Who’s at Risk?
    18/09/2025
    बिग बॉस 19: नॉमिनेशन की प्रक्रिया पूरी, कौन है सुरक्षित और कौन हुआ नॉमिनेट?
    बिग बॉस 19: नॉमिनेशन की प्रक्रिया पूरी, कौन है सुरक्षित और कौन हुआ नॉमिनेट?
    18/09/2025
    🧨 बिग बॉस 19 नॉमिनेशन टास्क: सजा का ऐलान! | बिग बॉस ने पलटा पासा!
    🧨 बिग बॉस 19 नॉमिनेशन टास्क: सजा का ऐलान! | बिग बॉस ने पलटा पासा!
    18/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • june
  • Business
  • july
  • announced
  • today
  •  and
  •  the
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Business

Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025

Business Wire
Last updated: 01/06/2025 3:53 AM
Business Wire
Share
4 Min Read
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
SHARE
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025

BEIJING–(BUSINESS WIRE)–Beijing Avistone Biotechnology Co., Ltd (“Avistone”), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.

- Advertisement -


- Advertisement -

The details of the poster presentation are provided below:

Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study

Abstract Number For Publication: 8632

Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic

Location: Poster Board, 112

Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT

- Advertisement -

MET amplification or overexpression is the most common “off-target” mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure.

- Advertisement -

Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed.

A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure.

- Advertisement -

To obtain a copy of the poster, please email Avistone.

- Advertisement -

About Vebreltinib

Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification.

- Advertisement -

About Andamertinib (PLB1004)

- Advertisement -

Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity.

About Avistone Biotechnology

- Advertisement -

Beijing Avistone Biotechnology Co., Ltd. (“Avistone”) is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.

- Advertisement -

Contacts

BD@avistonebio.com

- Advertisement -
Afcons elevates Shapoorji Mistry as Chairman – Emeritus, Krishnamurthy Subramanian as Executive Chairman, and inducts Pallon S Mistry to its Board
Telangana Leads with Long-Term Financial Thinking: 94% Prefer to Plan Ahead, 87% Consider Life Insurance Savings Plans
Nomad Internet Launches First-Ever Nationwide Free Internet Service for RV Parks
Millimans first-ever Registered Index-Linked Annuity Experience Study shows behavior similarities with multi-year guaranteed annuity contract holders
ATLANTIC-ACM Announces 2025 U.S. Business Connectivity Service Provider Excellence Awards
TAGGED:andamertinibannouncedavistonebeijingbusinessbiotechnologyclinicalcombinationcompanydataepidermalfactorfocusedgrowthinhibitorinnovativeltdmesenchymalepithelialmetoncologyplbplusposterpotentprecisionsessiontherapeuticstodaytransitionvebreltinibwirebeijing
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Draganfly Announces Closing of US.75 Million Public Offering
Tech

Draganfly Announces Closing of US$13.75 Million Public Offering

13/06/2025
Amazon Launches Infrastructure Region in New Zealand
Business

Amazon Launches Infrastructure Region in New Zealand

02/09/2025
Hello Sunshine Launches Sunnie, New Multimedia and Experiential Brand for and by the Next Generation of Storytellers, Creators, and Changemakers
Business

Hello Sunshine Launches Sunnie, New Multimedia and Experiential Brand for and by the Next Generation of Storytellers, Creators, and Changemakers

18/06/2025
Costa Coffee Turns 20: A Legacy of Flavor, Connection, and Growth in India
Food

Costa Coffee Turns 20: A Legacy of Flavor, Connection, and Growth in India

08/09/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?